Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

PURPOSE: No standard treatment exists for patients with cholangiocarcinoma for whom first-line gemcitabine-based therapy fails. Fibroblast growth factor receptor 2 (FGFR2) fusions/translocations are present in 13% to 17% of intrahepatic cholangiocarcinomas. BGJ398, an orally bioavailable, selective...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Javle, Milind, Lowery, Maeve, Shroff, Rachna T., Weiss, Karl Heinz, Springfeld, Christoph, Borad, Mitesh J., Ramanathan, Ramesh K., Goyal, Lipika, Sadeghi, Saeed, Macarulla, Teresa, El-Khoueiry, Anthony, Kelley, Robin Kate, Borbath, Ivan, Choo, Su Pin, Oh, Do-Youn, Philip, Philip A., Chen, Li-Tzong, Reungwetwattana, Thanyanan, Van Cutsem, Eric, Yeh, Kun-Huei, Ciombor, Kristen, Finn, Richard S., Patel, Anuradha, Sen, Suman, Porter, Dale, Isaacs, Randi, Zhu, Andrew X., Abou-Alfa, Ghassan K., Bekaii-Saab, Tanios
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2018
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6075847/
https://ncbi.nlm.nih.gov/pubmed/29182496
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.75.5009
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados